Activation of signaling effectors by G-protein coupled receptors (GPCRs) depends on different molecular mechanisms triggered by conserved amino acid residues. Although studies have focused on the G-protein signaling state, the mechanism for β-arrestin signaling by CB1 is not yet well defined. Studies have indicated that transmembrane helix 7 (TMH7) and the highly conserved NPXXY motif can be subject to different conformational changes in response to biased ligands and could therefore participate in a molecular mechanism to trigger β-arrestin recruitment.
Objective:
To investigate the effect of mutations in the NPXXY motif on different signaling pathways activated by the CB1 receptor.
Materials and Methods:
Point mutations of the NPXXY motif and associated residues were generated in the CB1 receptor using site-directed mutagenesis and transfection into HEK-293 cells. Signaling by wild-type and mutant receptors was analyzed by quantifying inhibition of cAMP, and by β-arrestin recruitment assays.
Results:
We found that N7.49 and Y7.53 are essential for β-arrestin recruitment by CB1. N7.49A and Y7.53F impair β-arrestin signaling, with no effect on G-protein signaling. We found a regulatory role for residue I2.43; I2.43 interacts with Y7.53, affecting its positioning. Reducing steric bulk at I2.43 (I2.43A) enhances β-arrestin1 recruitment, while introducing a polar residue (I2.43T) reduces β-arrestin recruitment.
Conclusions:
These findings point to a novel mechanism for β-arrestin recruitment, implicating amino acids in the NPXXY motif as critical for the putative β-arrestin biased conformational state of Class A GPCRs.
Get full access to this article
View all access options for this article.
References
1.
MatsudaLA, LolaitSJ, BrownsteinMJ, et al.Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346:561–564.
2.
DevaneW, HanusL, BreuerA, et al.Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258:1946–1949.
3.
SugiuraT, KondoS, SukagawaA, et al.2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995; 215:89–97.
4.
MechoulamR, Ben-ShabatS, HanusL, et al.Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995; 50:83–90.
5.
ShenoySK, DrakeMT, NelsonCD, et al.Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem. 2006; 281:1261–1273.
6.
LiuJJ, HorstR, KatritchV, et al.Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science. 2012; 335:1106–1110.
7.
TanL, YanW, McCorvyJD, et al.Biased ligands of G protein-coupled receptors (GPCRs): structure-functional selectivity relationships (SFSRs) and therapeutic potential. J Med Chem. 2018; 61:9841–9878.
8.
HowlettAC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol. 1995; 35:607–634.
9.
LaprairieRB, BagherAM, KellyMEM, et al.Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J Biol Chem. 2014; 289:24845–24862.
10.
IbsenMS, FinlayDB, PatelM, et al.Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: species, subtype, and agonist-dependence. Front Pharmacol. 2019; 10:350.
11.
CristinoL, BisognoT, Di MarzoV. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020; 16:9–29.
12.
Fraguas-SánchezAI, Torres-SuárezAI. Medical use of cannabinoids. Drugs. 2018; 78:1665–1703.
13.
Delgado-PerazaF, AhnKH, Nogueras-OrtizC, et al.Mechanisms of biased β-arrestin-mediated signaling downstream from the cannabinoid 1 receptor. Mol Pharmacol. 2016; 89:618–629.
14.
KhajehaliE, MaloneDT, GlassM, et al.Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Mol Pharmacol. 2015; 88:368–379.
15.
HuaT, VemuriK, NikasSP, et al.Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. 2017; 547:468–471.
16.
HuaT, VemuriK, PuM, et al.Crystal structure of the human cannabinoid receptor CB1. Cell. 2016; 167:750.e14–762.e14.
17.
Krishna KumarK, Shalev-BenamiM, RobertsonMJ, et al.Structure of a signaling cannabinoid receptor 1-G protein complex. Cell. 2019; 176:448.e12–458.e12.
18.
CarpenterB, TateCG. Active state structures of G protein-coupled receptors highlight the similarities and differences in the G protein and arrestin coupling interfaces. Curr Opin Struct Biol. 2017; 45:124–132.
19.
GurevichVV, GurevichEV. Molecular mechanisms of GPCR signaling: a structural perspective. Int J Mol Sci. 2017; 18:2519.
20.
WeisWI, KobilkaBK. The molecular basis of G protein–coupled receptor activation. Annu Rev Biochem. 2018; 87:897–919.
21.
JiS, YangW, YuW. Understanding the role of the CB1 toggle switch in interaction networks using molecular dynamics simulation. Sci Rep. 2021; 11:22369.
22.
BallesterosJA, WeinsteinH. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In Receptor molecular biology, Sealfon SC, ed. New York, NY: Academic Press, 1995, pp. 366–428.
23.
HuaT, LiX, WuL, et al.Activation and signaling mechanism revealed by cannabinoid receptor-G(i) complex structures. Cell. 2020; 180:655.e18–665.e18.
24.
RanjanR, DwivediH, BaidyaM, et al.Novel structural insights into GPCR–β-arrestin interaction and signaling. Trends Cell Biol. 2017; 27:851–862.
25.
JinW, BrownS, RocheJP, et al.Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci. 1999; 19:3773–3780.
26.
HuangW, MasureelM, QuQ, et al.Structure of the neurotensin receptor 1 in complex with β-arrestin 1. Nature. 2020; 579:303–308.
27.
StausDP, HuH, RobertsonMJ, et al.Structure of the M2 muscarinic receptor–β-arrestin complex in a lipid nanodisc. Nature. 2020; 579:297–302.
28.
CahillTJ, 3rd, ThomsenAR, TarraschJT, et al.Distinct conformations of GPCR-beta-arrestin complexes mediate desensitization, signaling, and endocytosis. Proc Natl Acad Sci U S A. 2017; 114:2562–2567.
29.
KumariP, SrivastavaA, GhoshE, et al.Core engagement with beta-arrestin is dispensable for agonist-induced vasopressin receptor endocytosis and ERK activation. Mol Biol Cell. 2017; 28:1003–1010.
30.
FayJF, FarrensDL. A key agonist-induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569. J Biol Chem. 2012; 287:33873–33882.
31.
FayJF, FarrensDL. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1. Proc Natl Acad Sci U S A. 2015; 112:8469–8474.
32.
RahmehR, DamianM, CottetM, et al.Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci U S A. 2012; 109:6733–6738.
33.
WinglerLM, ElgetiM, HilgerD, et al.Angiotensin analogs with divergent bias stabilize distinct receptor conformations. Cell. 2019; 176:468.e11–478.e11.
34.
ErlandsonSC, McMahonC, KruseAC. Structural basis for G protein-coupled receptor signaling. Annu Rev Biophys. 2018; 47:1–18.
35.
HuangW, ManglikA, VenkatakrishnanAJ, et al.Structural insights into μ-opioid receptor activation. Nature. 2015; 524:315–321.
36.
GripentrogJM, JesaitisAJ, MiettinenHM. A single amino acid substitution (N297A) in the conserved NPXXY sequence of the human N-formyl peptide receptor results in inhibition of desensitization and endocytosis, and a dose-dependent shift in p42/44 mitogen-activated protein kinase activation and chemotaxis. Biochem J. 2000; 352:399–407.
37.
KalatskayaI, SchüsslerS, BlaukatA, et al.Mutation of tyrosine in the conserved NPXXY sequence leads to constitutive phosphorylation and internalization, but not signaling, of the human B2 bradykinin receptor. J Biol Chem. 2004; 279:31268–31276.
38.
RagnarssonL, Andersson Å, ThomasWG, et al.Mutations in the NPxxY motif stabilize pharmacologically distinct conformational states of the α 1B- and β 2-adrenoceptors. Sci Signal. 2019; 12:eaas9485.
39.
WackerD, WangC, KatritchV, et al.Structural features for functional selectivity at serotonin receptors. Science. 2013; 340:615–619.
40.
SuomivuoriC-M, LatorracaNR, WinglerLM, et al.Molecular mechanism of biased signaling in a prototypical G protein–coupled receptor. Science. 2020; 367:881–887.
41.
GamageTF, AndersonJC, AboodME. CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling. Cannabis Cannabinoid Res. 2016; 1:272–280.
42.
TaoQ, AboodME. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther. 1998; 285:651–658.
43.
MiessE, GondinAB, YousufA, et al.Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization. Sci Signal. 2018; 11:eaas9609.
44.
GaraiS, LeoLM, SzczesniakA-M, et al.Discovery of a biased allosteric modulator for cannabinoid 1 receptor: preclinical anti-glaucoma efficacy. J Med Chem. 2021; 64:8104–8126.
45.
KapurA, HurstDP, FleischerD, et al.Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol. 2007; 71:1512–1524.
46.
MarcuJ, ShoreDM, KapurA, et al.Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2. J Pharmacol Exp Ther. 2013; 345:189–197.
47.
AbadjiV, Lucas-LenardJM, ChinCN, et al.Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of G(s). J Neurochem. 1999; 72:2032–2038.
48.
EldeebK, Leone-KablerS, HowlettAC. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function. J Basic Clin Physiol Pharmacol. 2016; 27:311–322.
49.
GlassM, FelderCC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci. 1997; 17:5327–5333.
50.
MangmoolS, KuroseH. Gi/o protein-dependent and -independent actions of pertussis toxin (PTx). Toxins. 2011; 3:884–899.
51.
EldeebK, Leone-KablerS, HowlettAC. Mouse neuroblastoma CB1 cannabinoid receptor-stimulated [35S]GTPɣS binding: total and antibody-targeted Gα protein-specific scintillation proximity assays. In Methods in enzymology, Reggio PH, ed. New York, NY: Academic Press, 2017, pp. 1–21.
52.
YuanS, FilipekS, PalczewskiK, et al.Activation of G-protein-coupled receptors correlates with the formation of a continuous internal water pathway. Nat Commun. 2014; 5:4733.
53.
AhnKH, MahmoudMM, KendallDA. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem. 2012; 287:12070–12082.
54.
PriceMR, BaillieGL, ThomasA, et al.Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005; 68:1484–1495.
55.
AhnKH, MahmoudMM, ShimJY, et al.Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem. 2013; 288:9790–9800.
56.
ShaoZ, YanW, ChapmanK, et al.Structure of an allosteric modulator bound to the CB1 cannabinoid receptor. Nat Chem Biol. 2019; 15:1199–1205.
57.
SchneiderM, KasanetzF, LynchDL, et al.Enhanced functional activity of the cannabinoid type-1 receptor mediates adolescent behavior. J Neurosci. 2015; 35:13975–13988.
58.
HurstDP, GaraiS, KulkarniPM, et al.Identification of CB1 receptor allosteric sites using force-biased MMC simulated annealing and validation by structure-activity relationship studies. ACS Med Chem Lett. 2019; 10:1216–1221.
59.
SinghR, HurstDP, Barnett-NorrisJ, et al.Activation of the cannabinoid CB1 receptor may involve a W6 48/F3 36 rotamer toggle switch. J Pept Res. 2002; 60:357–370.
60.
McAllisterSD, HurstDP, Barnett-NorrisJ, et al.Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem. 2004; 279:48024–48037.
61.
LynchDL, HurstDP, ShoreDM, et al.Molecular dynamics methodologies for probing cannabinoid ligand/receptor interaction. Methods Enzymol. 2017; 593:449–490.
62.
StornaiuoloM, BrunoA, BottaL, et al.Endogenous vs exogenous allosteric modulators in GPCRs: a dispute for shuttling CB1 among different membrane microenvironments. Sci Rep. 2015; 5:15453.
63.
ValléeM, VitielloS, BellocchioL, et al.Pregnenolone can protect the brain from cannabis intoxication. Science. 2014; 343:94–98.
64.
BarakLS, MenardL, FergusonSSG, et al.The conserved seven-transmembrane sequence NP(X)2,3Y of the G-protein-coupled receptor superfamily regulates multiple properties of the beta2-adrenergic receptor. Biochemistry. 1995; 34:15407–15414.
65.
FenaltiG, GiguerePM, KatritchV, et al.Molecular control of δ-opioid receptor signalling. Nature. 2014; 506:191–196.
66.
BarakLS, TiberiM, FreedmanNJ, et al.A highly conserved tyrosine residue in G protein-coupled receptors is required for agonist-mediated beta 2-adrenergic receptor sequestration. J Biol Chem. 1994; 269:2790–2795.
67.
GabilondoAM, KraselC, LohseMJ. Mutations of Tyr326 in the β2-adrenoceptor disrupt multiple receptor functions. Eur J Pharmacol. 1996; 307:243–250.
68.
LaporteSA, ServantG, RichardDE, et al.The tyrosine within the NPXnY motif of the human angiotensin II type 1 receptor is involved in mediating signal transduction but is not essential for internalization. Mol Pharmacol. 1996; 49:89–95.
69.
BondeMM, HansenJT, SanniSJ, et al.Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms. PLoS One. 2010; 5:e14135.
70.
HeR, BrowningDD, YeRD. Differential roles of the NPXXY motif in formyl peptide receptor signaling. J Immunol. 2001; 166:4099–4105.
71.
BouleyR, SunT-X, ChenardM, et al.Functional role of the NPxxY motif in internalization of the type 2 vasopressin receptor in LLC-PK1 cells. Am J Physiol Cell Physiol. 2003; 285:C750–C762.
72.
KramerHK, AndriaML, KushnerSA, et al.Mutation of tyrosine 318 (Y318F) in the delta-opioid receptor attenuates tyrosine phosphorylation, agonist-dependent receptor internalization, and mitogen-activated protein kinase activation. Brain Res Mol Brain Res. 2000; 79:55–66.
73.
KatritchV, FenaltiG, AbolaEE, et al.Allosteric sodium in class A GPCR signaling. Trends Biochem Sci. 2014; 39:233–244.
74.
ShaoZ, YinJ, ChapmanK, et al.High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature. 2016; 540:602–606.
